

**MERCK**

# DARE to collaborate

**Merck Innovation Hub China**  
**Merck Accelerator China 3rd Intake**  
**Join forces with us!**





## Apply now for the 3rd intake of the Merck Accelerator China!

Merck has opened a new round of applications for startups to participate in the Merck Accelerator China program.

**The 3-month program runs two intakes per year in Shanghai and Guangdong aiming to identify promising startups to connect and explore collaboration opportunities with Merck. The goal is to create a win-win partnership through developing a pilot project leveraging your and Merck's expertise.**

Applications for the third intake are open from March 3rd until May 17th, and all the applications will be evaluated by China and global experts to identify the right to fit for Merck. The program accelerates startups in the early stage to growth stage in the fields of healthcare, performance materials and life sciences. Especially fields including AI-enabled healthcare solutions, organoids, bioelectronics, liquid biopsy technologies, neuromorphic systems and clean meat are of interest.

**Application Opens:** March 3rd – May 17th, 2020

**Program Starts:** July 2020

**Location:** Shanghai, Guangdong, Beijing

**Result Notification:** You will receive the application result by email in June

**Contact Us:** [Innovation\\_China@merckgroup.com](mailto:Innovation_China@merckgroup.com)

**Apply Now:** [acceleratorchina.merckgroup.com](https://acceleratorchina.merckgroup.com)



# We are looking for startups in the fields of

## Healthcare

Our Biopharma business discovers, develops, manufactures and markets innovative pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis (MS), infertility, growth disorders as well as certain cardiovascular and metabolic diseases.

- Patient-centric beyond-the-pill solutions, e.g. for lifestyle intervention or disease management
- Connected health devices
- Diagnostic and patient detection methods to improve diagnostic rates or to identify potential patients
- Enabling methods for global translational medicine in line with individual and national privacy requirements

## Life Science

Innovative tools and laboratory supplies for the life science industry that make research and biotech production better, faster and safer.

- New Research Tools/Kits in Biology, Chemistry or Material Science
  - Molecular platforms (e.g. NGS sample and library prep, Single cell analysis, Microbiology, Epigenetics, Cloning, Expression)
  - Immunoassay platform solutions
  - Protein & Antibody technologies
  - Cell culture technology (e.g. organoids)
  - Material sciences (e.g. Nanoparticles, Drug delivery formulations, Biocompatible polymers, 3D Bioprinting inks)
  - New chemicals (e.g. DNA encoded Libraries (DEL), Stable Isotopes)
  - Molecular workflow tools and labware
- New Biopharma Technology
  - ADCs
  - Microbiome
  - Metabolics
- End-to-End Bioprocessing
  - Next-generation Bioprocessing
  - Single-use disposable equipment
  - Continuous manufacturing
  - Viral & gene, cellular and RNA therapies
- Connected Labs
- Food and Environmental Monitoring
  - Food Safety / Food Supply Chain

## Performance Materials

Our specialty chemicals business is combined in our Performance Materials business sector. A wide range of high-tech chemicals, such as specialty chemicals for the semiconductor industry, liquid crystals and OLED materials for displays & lighting, effect pigments for coatings and cosmetic products.

- Semiconductor Materials / Devices / Labs / Platforms
- Electro-Optical devices
- Electronic packaging & interconnects
- OLED Materials
- Display technologies
- Advanced emergent sensors
- Smart windows/antennas
- Automotive applications around displays, surface and semi chips

## AI-enabled Health Solutions

This field is defined as AI-based, mainly data mining and machine learning based, new technologies, products and services, which can impact medical or healthcare industry across value chain in value-added ways such as increasing efficiency, saving cost, and/or improving customer experience.

- AI-enabled follow-up on patient with chronic diseases and Clinical Decision Support System
- AI-assisted (early) diagnosis rate improvement in leading therapeutic areas (TAs) like diabetes, thyroid, fertility and Ras wild type colorectal cancer
- AI-enabled clinical research & development

## Bioelectronics

It represents the symbiosis of Bioelectronic Medicine and Biosensing. Bioelectronic Medicine is a new approach that uses stimulation of the Central or Peripheral Nervous System to treat diseases. This segment shows great potential in indications ranging from Diabetes to MS and it is expected to enhance the therapeutic effectiveness while having less side effects, shorter development cycles and lower R&D costs than conventional pharmaceuticals.

## Clean Meat

This field focuses on the biotechnology required to produce food that is healthier, more efficiently produced, ethical and environmentally sustainable.

- Technologies to enable economically viable, large-scale production of clean meat and seafood such as animal component-free media, high-yield cell line development, industrial bioreactors or automation platform
- Technologies similar to tissue engineering and regenerative medicine, to enable next-generation of structured products such as edible scaffolds/biomaterials, 3D cell culture processes, 3D printing



## Liquid Biopsy Technologies

A liquid biopsy is a simple and non-invasive test to identify various diseases by detecting biomarkers in body fluids. It is a key technology for early disease detection and expanding the delivery of precision medicine to more patients. This field focuses on technological solutions to overcome unresolved challenges in the liquid biopsy workflow as well as on applications beyond cancer.


- New technologies that help overcome bottlenecks in the liquid biopsy workflow such as the isolation of specific body fluid components or biomarkers
- Liquid biopsies for indications beyond oncology where existing diagnosis or surveillance methods are inadequate and have significant limitations due to their invasiveness Smart in-patient (bed) management

## Organoids

Organoids is an emerging 3D cell culture system that organizes tissue cultures from stem cells. These cultures can be crafted to replicate simplified versions of organs that vary depending on the different organ types.

## Neuromorphic Systems

This thriving area aims to mimic the working principles of our brain to increase computing power and decrease power consumption of the next generation computing. It also addresses the problem of the massively growing carbon footprint of our current technologies.



# our offerings



## Partnership

Access to Merck China resources and intensive exploration of partnership opportunities through pilot project development



## Ecosystem

Be part of the most dynamic startup ecosystems in the world and visit our sites with different business focus in Shanghai, Guangzhou and Beijing



## Alumni

Access to Merck global startups alumni network, partner up with peers in relevant fields to grow your business



## Co-creation Space

Modern workspace in our Innovation Hub in Shanghai and Guangzhou



## Events

Gain exposure and visibility to investors and other business partners through participation on various industry leading events



## Funding

Receive funding up to €50,000 and the chance to get additional investment opportunities



## Curriculum

Benefit from tailored coaching sessions, workshops and innovate together with our senior experts and external mentors



# About Merck and innovation hub china

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices—the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

As an important part of Merck's global innovation network, Merck Innovation Hub China scouts, incubates and invests in innovative opportunities in healthcare, life science, performance materials and related fields between and beyond the existing businesses. Embedded into China's innovation ecosystem, Merck Innovation Hub China is committed to partnering with start-ups, academic institutions, industry players and local governments, combining unique technology and expertise from Merck Group and collaborators with the goal to develop novel technology and bring new solutions to the market for China and global. The China Innovation Hub also provides support of ideation, incubation and trainings to local talents, partners and Merck employees to build win-win collaboration.

For more information, please visit  
<http://innovateinchina.merckgroup.com>.

Or follow our WeChat account.



**57,000**

Employees worldwide



**66**

Countries



**1668**

Founded



**2.3**


R&D (€ billion)



**16.2**

Sales(€ billion)





**TAKE YOUR CHANCE  
JOIN FORCES WITH MERCK!**

**Apply Now!**



**2020.03.03-2020.05.17  
[acceleratorchina.merckgroup.com](https://acceleratorchina.merckgroup.com)**